Servier Italy Welcomes Emilio Gagliardi as President, Charting a Course for Innovation and Patient Access
Milan, Italy – October 26, 2023 – In a significant leadership change poised to reshape Servier’s Italian operations, Emilio Gagliardi has been appointed as the new President of Servier Italy, effective immediately. This breaking news marks a pivotal moment for the French multinational pharmaceutical giant, which ranks 4th globally in turnover and 1st in Europe, and now expands Gagliardi’s remit to include oversight of Malta as well.
A Proven Leader Takes the Helm
Gagliardi brings to the role over two decades of extensive experience within the pharmaceutical industry, coupled with a strong track record in business management. He’s not a newcomer to Servier, having previously served as Commercial Director for Servier Italia and holding key positions within Servier Global, including Deputy Operation Director for Brazil and Argentina, Managing Director for Servier Bulgaria, and most recently, Managing Director of Servier Middle East.
His career began at AstraZeneca, providing a broad foundation for his subsequent successes. Gagliardi’s expertise spans critical therapeutic areas like cardiology, diabetology, and oncology, and he’s consistently demonstrated an ability to blend strategic vision with practical, innovative solutions. He holds a degree in Molecular Biology from the University of Florence and a specialization in Finance and General Management from SDA Bocconi, further solidifying his well-rounded business acumen.
Strategic Focus: Oncology, Cardiology, and Sustainable Healthcare
Gagliardi’s primary mission is to steer Servier Italy towards achieving the group’s ambitious 2030 objectives. He emphasized a commitment to not only business growth but also a deep dedication to patient needs, robust research and development, and the principles of sustainable development and corporate social responsibility. This isn’t just about profits; it’s about making a tangible difference in the lives of patients.
“Taking Servier’s guide in Italy…represents a great honor,” Gagliardi stated. “Together with all colleagues, we will continue to pursue the group’s objectives with determination, working to guarantee patients timely access of innovative therapeutic solutions in oncology and cardiology.”
Precision Oncology and Chronic Disease Management
Servier Italy, under Gagliardi’s leadership, will prioritize consolidating its leadership position in cardiology, focusing on collaborative partnerships within the Italian healthcare system to improve the management of chronic diseases. This “grip with cure” approach – a proactive, holistic strategy – aims to enhance both individual health outcomes and the long-term sustainability of the National Health Service (NHS).
Oncology will remain a key growth area, with a specific ambition to become a leading force in precision oncology. This involves developing and delivering treatments tailored to individual patients’ tumor profiles, addressing unmet medical needs in complex cancer cases. Precision oncology represents the future of cancer care, moving away from a one-size-fits-all approach to highly targeted therapies.
A Smooth Transition and a Legacy of Leadership
Emilio Gagliardi succeeds Gilles Renacco, who served as President of Servier Italy from October 2021 to September 2023. Renacco’s tenure laid a strong foundation for continued growth and innovation, and Gagliardi is poised to build upon that success.
The appointment of Gagliardi signals Servier’s continued investment in the Italian market and its commitment to delivering cutting-edge pharmaceutical solutions. His international experience and strategic vision will be invaluable as the company navigates the evolving healthcare landscape and strives to improve patient outcomes. This is a development to watch closely for anyone involved in the Italian pharmaceutical sector, and a testament to the growing importance of personalized medicine and sustainable healthcare practices. For the latest updates on Servier and the pharmaceutical industry, stay tuned to Archyde.com.
